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Abstract 
 
Objectives. To determine the general public’s preferences over the design and use of  
UK Biobank; and the design for optimum recruitment. 
Design. Discrete choice face-to-face interviews using a fractional factorial design and 
multinomial logit regression modelling. 
Setting. 180 sampling points across 11 regions of the UK. 
Participants. Members of the public. 
Main outcome measures. Relative risks of people’s preferences for project design 
and use. 
Results. 34.4% of respondents were willing to take part in UK Biobank (n=1283). 
The most highly preferred scenario was: individual feedback from the study; consent 
every time new data is requested; DNA and information destruction on withdrawal; 
and access to the data by the NHS and Universities but not other third parties.  
The single most important attribute was access to data. If individual’s insurance 
companies were to be given access to the data this would be the largest single 
impediment to recruitment to the study. Extra resources are likely to be needed to 
counter the reduced recruitment rate if pharmaceutical companies are allowed access 
to the data. 
Conclusions. The general public do have clear preferences regarding the design of 
biobanks. Whilst designing the study to meet the most preferred scenario may not be 
practical within available resources, biobanks can use the type of information 
provided here to compare the costs and benefits of different study designs. The 
‘price’of discounting public preferences in terms of reduced recruitment should be an 
important part of the ‘weighing’ process.  Pilot studies of recruitment under 
alternative study designs may be justified. 
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Introduction 
The Human Genome Project (HGP) has established the complete sequence of human 
DNA.1 2 Elucidation of the roles that genes play in health and disease requires large, 
prospective cohort studies that investigate the interactions between genes, lifestyle 
and the environment.3 With this in mind, many countries are setting up national 
cohorts, including Iceland, Estonia, Australia and the UK.4-7 If the public do not 
consent to these large DNA cohorts, then the potential of the HGP may never be 
realised. 
 
UK Biobank is a DNA cohort study funded jointly by the MRC, the Wellcome Trust 
and the Department of Health.7 It aims to recruit half a million volunteers aged 45-69 
years, through primary care. It will take DNA, medical and lifestyle information at 
baseline, and is likely to follow up the cohort for 10-20 years.  There are a number of 
unique features that warrant research. For example,  DNA will be taken and stored, 
many of the tests to be performed on the DNA will not be known at recruitment, and 
insurance, biotechnology, pharmaceutical companies and the police (amongst others) 
may be interested in the information produced. Whilst it is not proposed that 
insurance companies have access, concern that they may do could have an adverse 
effect on recruitment. 
 
The UK Government sees UK Biobank as “an invaluable resource for researchers 
seeking to establish the effects of our genes”. 8 As recently acknowledge by the House 
of Commons Science and Technology Select Committee, understanding individual’s 
preferences regarding the study design is a research priority.9   
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Conjoint analysis (CA) is a method for disaggregating individual’s preferences in 
multifactorial decision making environments, rooted in Lancaster’s theory of value.10 
CA presents individuals with one or more pairwise choices, and asks them to choose 
which scenario they prefer. A scenario is constructed from a number of attributes, 
where each attribute is considered to be a potentially important determinant of the 
decision. An attribute can have two or more levels. A scenario consists of one level on 
each of the attributes. An example of a pairwise choice is given in Figure 1. Whilst 
the interview process can be time consuming and the task cognitively demanding, the 
approach provides more information than Likert and ranking questionnaires.11 
 
CA was developed in mathematical psychology, and has been widely used in 
transport and environmental economics.11 Subsequently, it has been used in healthcare 
including eliciting patient preferences in the delivery of health services and doctor 
preferences regarding characteristics of their job.12-14 This study used CA to examine 
the public’s preferences for the study design of UK BioBank. However the 
methodological issues of consent, feedback, withdrawal and access are common 
problems faced by those establishing biobanks elsewhere. 
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 Methods 
Public attitudes to participation in a large DNA cohort study were measured by face-
to-face conjoint interviews. Interview schedules were designed on the basis of known 
concerns with the UK Biobank protocol.15 16 These concerns were used to formulate 
attributes of paired scenarios, each of which consisted 2-4 levels (see table 1).  
 
The attribute levels generate 72 scenarios (the product of the number of levels for 
each attribute; 3x2x3x4). An orthogonal array consisting of 16 scenarios produced 
120 pairwise choices. As no one individual could provide data on all the choices, the 
scenarios were allocated across 10 questionnaires. 
 
Interviews were conducted with 1283 members of the public in 180 centres across 11 
regions of mainland Great Britain, using stratified sampling representative of the 
British population.  A market research company was hired to administer the 
questionnaires as they have a network of interviewers that facilitates nation-wide 
sampling. The interviewers underwent common training. The interviews were 
administered face-to-face in people’s homes. They were preceded by general 
demographic questions and followed by questions commissioned by commercial 
clients.  Each interview began with an introductory explanation of UK Biobank, and 
an explanation of the nature of conjoint questionnaires, in particular how the scenarios 
are hypothetical and how participants are asked to imagine they really have to choose 
between two options (see figure 2). Respondents were also asked about their age, sex, 
ethnic group, social grade, terminal educational age, income, lifestage, marital status, 
children, employment status and housing. In addition, respondents’ willingness to 
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participate in the UK Biobank study was measured at the end of the interview using a 
visual analogue scale. The questionnaires were piloted on a selection of researchers 
for comprehension and for time taken to complete the interview. Fieldwork was 
conducted during the third week of January 2002. Each interviewer was given a set of 
around 120 addresses, selected by ACORN profiling, and had to achieve a quota of 
12-15 interviews from these 120 addresses. Show cards were used to display conjoint 
pairs of scenarios to choose from, and likert scales where appropriate. Interviewers 
asked for the respondents to give their first impression as to which scenario they 
prefered, although a “no preference” option was allowed. Responses were entered 
directly onto a laptop computer. 
 
A multinomial logit regression model clustered on the individual was constructed in 
STATA v7, as the discrete dependent variable had three possible outcomes with no 
natural ordering. A separate model was estimated for the over 45 years of age sub-
sample (the population from which UK Biobank will recruit).Within sample 
predictive performance was assessed by the level of agreement between observed 
modal responses and predicted responses, with non-dominant pairs (where the model 
cannot be expected to predict) removed. External predictive validity was established 
by testing the model on another conjoint dataset constructed as part of a parallel study 
on UK Biobank performed in North East Derbyshire. This dataset comprised 665 
responses to a postal survey of 2000 people sampled from the electoral register.  
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 Results 
The responses per pairwise choice ranged from 95 to 155 (n=1283). Thirty four per 
cent (n=441) were willing to take part in UK Biobank after having completed the 
questionnaire.  
 
In order to exclude noise from the model (as indifference may mean true indifference 
between two options that are equally liked or disliked, or inability to decide because 
of lack of motivation or time) an incremental exclusion of respondents based upon 
proportion of answers being indifferent was carried out. This was performed 
iteratively until modelling preferring A over B gave the same model as preferring B 
over A, but with the opposite sign. The models became stable when those individuals 
who answered 9 or more questions (out of a possible 12 or 13) as indifferent were 
excluded. The final model included 79.4% of the initial dataset (n=1019). The 
excluded group was not significantly different from the final dataset for sex, ethnic 
group or social grade. There was a significant difference for age due to a cohort effect 
(percentage over 65 years in final dataset=16.5%, in the excluded group=26.4%; χ2 
excluding over 65 category, χ2=2.18, p= 0.70, df=4).  
 
Multinomial logit regression produced two sets of coefficients; first, those explaining 
respondents’ choice of A over B and second, those explaining respondents’ preference 
for indifference over choosing scenario B. The first set is presented in Table 2. A 
positive coefficient means that the attribute level contributes to a choice between 
scenarios by increasing the probability of the individual preferring the option 
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containing the attribute level to the reference level. When exponentiated, this 
translates to a relative risk (RR)>1.  
 
The population was half as likely to choose a scenario with no feedback as a 
component compared to a scenario with individual feedback. There was no significant 
difference between preferences for feedback to GP compared to individual feedback. 
 
Participants were 23% less likely to choose a scenario if consent was obtained only at 
recruitment.  
 
Respondents did not exhibit strong preferences for the arrangements on withdrawal 
from the study. The most popular option was to destroy the DNA but to use the 
information collected. However, the RR was small, and the 95% confidence intervals 
overlapped with alternative options.  
 
Preferences were much more distinct regarding access to data. The preferred option 
was for the NHS and Universities only to have access.  This was strongly preferred to 
biotechnology companies and the police (RR 0.71 and 0.74 respectively); which were 
in turn strongly preferred to insurance companies (RR 0.39).  
 
The coefficients for preferring A over B therefore showed that the optimum scenario 
for patient participation is likely to be:  
? feedback direct to individual or via GP;  
? consent every time new data is requested; 
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?  DNA destroyed but information retained on withdrawing from the study or all 
DNA and data retained for use by the study; and 
? access by NHS and Universities only to the data. 
 
The most influential items on preferences as indicated by the relative size of the 
coefficients were, in descending order: insurance company access, not receiving 
feedback, drug and biotech access, police access and consent only at the start.  
 
Preferences of 45yrs and over participants (i.e. the UK Biobank age group) were not 
significantly different (see table 2). 
 
Table 3 shows the most and least preferred scenarios as predicted by the model. These 
are a product of both sets of coefficients and can be slightly different to when one set 
only is used. The 18 most popular scenarios all contained consent every time. There 
was some trading of access by biotechnology companies and the police (but not 
insurance companies) in order to retain this consent design. Consent just at the start of 
the study became acceptable provided that access was only given to NHS and 
universities, or if participants had the option to have everything destroyed on 
withdrawal (scenario ranks 19-28).  
 
The least preferred scenarios contained no feedback (ranks 59-72) and access by 
insurance companies (ranks 67-72). Participants chose a scenario containing no 
feedback if offered consent every time new information is requested (ranks 44-51). 
There was evidence of trading of attributes, where the opportunity of including some 
attributes in the study design was given up in order to retain more strongly preferred 
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options.  The highest rank achieved by a scenario containing no feedback (rank 29) 
involved trading of feedback from the study against choosing consent every time, 
destroying everything on withdrawal, and limiting access to NHS and Universities. 
The highest probability achieved by a scenario containing access by insurance 
companies (rank 36) involved trading of preferred access to the data against choosing 
feedback  coupled with consent every time new information is requested together with 
the option of destroying everything on withdrawal. Respondents may have felt that 
these characteristics would give them a veto over access by insurance companies. 
 
The model predicted internal and external datasets with 76% and 80% accuracy 
respectively, as measured by percentage agreement of observed modal responses with 
predicted values (with non-dominant pairs removed). The model predicted correctly 
97% of the time where percentage difference between the most common and second 
most common observed responses was greater than 20%, but was no better at 
predicting than tossing a coin when the difference fell below 20%. 
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Discussion 
Main Findings 
Approximately a third of those approached are likely to be willing to take part in 
Biobank. This is likely to be optimised by designing the study using the most 
preferred scenario identified by the conjoint analysis (individual feedback with 
consent every time new data is requested, DNA and information destruction on 
withdrawing from the study, together with access by NHS and Universities only to the 
data). Replacing individual feedback with GP feedback may reduce costs without 
impacting significantly upon recruitment. Substituting destruction of DNA but 
retention of information is likely to increase the long term value of Biobank without 
damaging recruitment.  
Strengths and weaknesses 
Given the imminence of and investment in DNA cohort studies world-wide, then this 
is timely research. It could be argued that this research may not reflect real 
preferences. There is early evidence from research into Chlamydia testing that 
expressed stated  preferences using a conjoint study design do reflect subsequent 
revealed preferences.17 Indifference created noise which affected the stability of 
models and data had to be excluded to remove the noise. This was not a fatal flaw in 
this study as the sample size was large, but may be an issue for smaller conjoint 
surveys. 
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 What does it mean in practice? 
The organisation responsible for administering UK Biobank will have to weigh up the 
costs and benefits of designing the study based on participant preference. Not taking 
preferences into consideration may affect recruitment rate and consequently cost and 
value of biobanks. However, ceding to participant preferences may be impractical or 
undesirable. 
 
People preferred some feedback (but had no preference as to whether this is direct to 
the individual or via the GP) but accurate and reliable individual feedback to half a 
million people represents a significant logistical challenge.  General as well as 
individual feedback was previously seen as a crucial motivator to participation.15 18 
GPs have expressed a wish to not have access to UK Biobank data, to avoid patients’ 
concerns about insurance company access.16 18 Individual feedback is not common in 
studies and is unlikely to have clinical significance for this study. It may be sensible 
not to arouse any expectations of feedback of this nature. 
 
Respondents preferred consent at every new data collection, but consent once for the 
entire period is more pragmatic and cheaper. Information about the uses to which the 
samples would be put, the unacceptability of mounting studies on diseases not named 
in the initial consent and assurance on confidentiality were seen as important in 
previous research. 15-16 18  GPs were very reluctant about releasing patient information 
without the patient providing consent on each occasion morbidity data is requested.16 
This may be especially important if the data is particularly sensitive or qualitatively 
different to that described at recruitment. Four out of five people in the People’s Panel 
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thought that specific consent should be sought for each test carried out on their 
DNA.18 BioBank participants will have their DNA examined on only a small number 
of occasions during the follow-up period. It may therefore be feasible to contact a 
participant on each occasion to check they are still willing to provide consent.  
 
A single consent at the start will have significant advantages for biobanks. It will cost 
less, will not depend on active participation by participants and will minimise non-
response bias.  The impossibility of potential research subjects knowing what 
information biobanks would access or what DNA tests they will do in the future does 
present an ethical concern, especially if a disease that recruits subsequently developed 
is associated with stigma, such as a mental disorder or a sexual problem.  
 
All three options for events on withdrawal were similar in their desirability to 
participants. Thus, given that destruction of information on withdrawal from the study 
is wasteful, then retention of all data should be the default design. Individuals who 
decide to withdraw may have strong views however. 
 
People preferred the NHS and universities only to have access to the data. Access for 
insurance companies was particularly unpopular in previous research.18 The latter has 
not been suggested for Biobank, but the strong opposition within this consultation 
suggests that this issue should be specifically addressed. Access by the police was 
unpopular but acceptable in certain circumstances. However, over 90 per cent of a 
MORI sample believed the police should have access to Biobank to enable their 
investigations into a murder or sexual assault.19 This may reflect a general wish for a 
police database, rather than allowing police access to a medical database. 
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 Drug and biotechnology company access was also unpopular, but acceptable under 
certain circumstances. Commercial access caused concern in previous research.15;18 
Income from commercial sources is likely to be actively sought. It might be argued 
that only these companies have the infrastructures necessary to translate the 
information provided by biobanks into health care interventions.  Encouragingly, 
previous research samples recognised and accepted this arguement.15 18 
 
However, recruitment is likely to be impaired to some degree by the explicit 
involvement of commercial organisations. If we assume that Biobank requires 
500,000 participants to meet the power requirements for the epidemiological 
hypotheses to be tested, then the numerical impact of allowing private sector access is 
a requirement to approach an additional 594,015 people.  Also if the preference 
against pharmaceutical company involvement is stronger in certain socio-economic 
groups, allowing access may lead to a non-representative genetic database.  
Future Research 
Pilot studies of recruitment are required to test out prospectively the hypotheses that 
have been generated by our analyses, as well as to identify any barriers to recruitment 
not apparent from this research. 
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Figure 1: Formulation for pairwise choices within 
conjoint analysis 
 
Which situation would you prefer? (please tick box below) 
 
 Research Project A Research Project B 
Who should get feedback about 
general health information found 
during the initial health check? 
GP No feedback 
How often would a person need 
to give consent? 
 
Just at the start Every time 
What should happen when 
someone wants to pull out of the 
study? 
 
Destroy all DNA and 
information 
Destroy DNA but 
information already 
collected could be used 
Who should be allowed to 
conduct research on the DNA 
and information? 
In addition to use for 
research, the police 
would also have access 
All researchers including 
drug and biotech 
companies 
 Prefer A  Prefer B  
 
Please tick one or both boxes 
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Table 1: Attributes and levels used to construct the 
conjoint scenarios. 
 
Attribute Level 0 Level 1 Level 2 Level 3 
Who should get 
feedback about 
general health 
information 
found during 
the initial health 
check? 
Individual 
participants 
Participant’s GP No feedback n/a 
How often 
would a person 
need to give 
consent? 
Every time new 
information is 
gathered 
Just at the start 
of the project 
n/a n/a 
What should 
happen when 
someone wants 
to pull out of the 
study? 
Destroy all 
DNA 
information 
Destroy DNA 
but  information 
already 
collected could 
be used 
Use DNA and 
information 
but no new 
information to 
be collected 
n/a 
Who should be 
allowed to 
conduct 
research on the 
DNA and 
information? 
NHS and 
Universities 
All researchers 
plus drug and 
biotech 
companies 
All 
researchers 
plus the 
individual’s 
insurance 
company 
All researchers 
plus the police 
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Table 2: Conjoint analysis of people’s preferences concerning participation in UK Biobank using 
multinomial logit regression (n=1019) 
 
Prefers A over B First model Final Model 
Attributes  Coefficient Std.
Error 
P  RR (95%CI) Coefficient Std. error RR (95%CI) 
Feedback  
Feedback to GP* 
 
-0.0027       0.0525 0.96 1.00 (0.90-1.11) n/a n/a n/a
No feedback* 
 
-0.6964 0.0454 0.00 0.50 (0.46-0.54) -0.6954 0.0403 0.50 (0.46-0.54) 
Consent        
Just at the start** 
 
-0.2657 0.0377 0.00 0.77 (0.71-0.83) -0.2658 0.0378 0.77 (0.71-0.83) 
Wishes on withdrawal from the study        
Destroy DNA but use information*** 
 
0.1608 0.0441 0.00 1.17 (1.08-1.28) 0.1606 0.0440 1.17 (1.08-1.28) 
Use both DNA and information already 
collected*** 
0.0832 0.0458 0.07 1.09 (0.99-1.19) 0.0827 0.0458 1.09 (0.99-1.19) 
Access to the data        
All researchers including drug and 
biotech companies**** 
-0.3485 0.0503 0.00 0.71 (0.64-0.78) -0.3466 0.0504 0.71 (0.64-0.78) 
All researchers plus individual’s 
insurance company**** 
-0.9452 0.0583 0.00 0.39 (0.35-0.44) -0.9431 0.0581 0.39 (0.35-0.44) 
All researchers plus police**** 
 
-0.2957 0.0585 0.00 0.74 (0.66-0.83) -0.2955 0.0583 0.74 (0.66-0.83) 
 
Reference level is * “Feedback to the individual” ** “Consent required every time”*** “Destroy all DNA and information” ****“NHS and Universities” 
 
n/a = not applicable (as not in final model).
 - 18 - 
 - 19 - 

 
 
Table 3.  Most and least preferred scenarios for UK 
Biobank design as predicted by a multinomial 
logit regression model (n=1019) 
 
Rank Feedback  Consent Withdrawal Access 
 
Ten most preferred 
1 Individual feedback every time destroy everything NHS and universities
2 Feedback to GP every time destroy everything NHS and universities
3 Individual feedback every time Use DNA and info NHS and universities
4 Feedback to GP every time Use DNA and info NHS and universities
5 Individual feedback every time destroy DNA use info NHS and universities
6 Feedback to GP every time destroy DNA use info NHS and universities
7 Individual feedback every time destroy everything biotech 
8 Feedback to GP every time destroy everything biotech 
9 Individual feedback every time destroy everything police 
10 Feedback to GP every time destroy everything police 
 
Ten least preferred 
63 No feedback just at the start Use DNA and info  biotech 
64 No feedback just at the start destroy DNA use info  biotech 
65 No feedback just at the start Use DNA and info  police 
66 No feedback just at the start destroy DNA use info police 
67 No feedback every time destroy everything insurance 
68 No feedback every time destroy DNA use info insurance 
69 No feedback every time Use DNA and info insurance 
70 No feedback just at the start destroy everything insurance 
71 No feedback just at the start destroy DNA use info insurance 
72 No feedback just at the start Use DNA and info insurance 
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